For research use only. Not for therapeutic Use.
MK-5172 (Cat No.:I001345) is a direct-acting antiviral (DAA) used in combination with Elbasvir to treat chronic hepatitis C virus (HCV) infection, particularly in genotypes 1 and 4. Grazoprevir is a potent inhibitor of the HCV NS3/4A protease, an enzyme crucial for viral replication. By blocking this protease, Grazoprevir prevents the virus from processing its proteins, halting its life cycle. When used with Elbasvir, it provides a highly effective, oral treatment with a high sustained virologic response (SVR), offering a cure for HCV in many patients with minimal side effects.
| Catalog Number | I001345 |
| CAS Number | 1350514-68-9 |
| Molecular Formula | C38H50N6O9S |
| Purity | 98% |
| Target | NS3/4a protease |
| Target Protein | Q5L478,B0B3C9 |
| Solubility | 10 mM in DMSO |
| Appearance | Solid |
| Storage | Dry, dark and at 2 - 8 °C for six months or -20°C for two years. |
| IC50 | EC50: 2 nM(genotype 1a) |
| IUPAC Name | (1R,18R,20R,24S,27S)-24-tert-butyl-N-[(1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-ethenylcyclopropyl]-7-methoxy-22,25-dioxo-2,21-dioxa-4,11,23,26-tetrazapentacyclo[24.2.1.03,12.05,10.018,20]nonacosa-3,5(10),6,8,11-pentaene-27-carboxamide |
| InChI | InChI=1S/C38H50N6O9S/c1-6-22-19-38(22,35(47)43-54(49,50)25-13-14-25)42-32(45)29-18-24-20-44(29)34(46)31(37(2,3)4)41-36(48)53-30-16-21(30)10-8-7-9-11-27-33(52-24)40-28-17-23(51-5)12-15-26(28)39-27/h6,12,15,17,21-22,24-25,29-31H,1,7-11,13-14,16,18-20H2,2-5H3,(H,41,48)(H,42,45)(H,43,47)/t21-,22-,24-,29+,30-,31-,38-/m1/s1 |
| InChIKey | OBMNJSNZOWALQB-NCQNOWPTSA-N |
| SMILES | CC(C)(C)[C@H]1C(=O)N2C[C@@H](C[C@H]2C(=O)N[C@@]3(C[C@H]3C=C)C(=O)NS(=O)(=O)C4CC4)OC5=NC6=C(C=CC(=C6)OC)N=C5CCCCC[C@@H]7C[C@H]7OC(=O)N1 |
| Reference | <p style=/line-height:25px/> |
